DiaMedica Therapeutics Inc (DMAC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $449.47M
Last updated: Nov 17, 2026 at 4:10 PM ET
DiaMedica Therapeutics Inc (DMAC) Statistics
DiaMedica Therapeutics (DMAC) has a market cap of $449.47M and an enterprise value of $442.67M. Revenue fell 100.20% over the last 12 months from the 12 months before. Its share count is up 8.69% from a year earlier.
Total Valuation
Enterprise value is 1.51% below the market cap, as cash exceeds debt.
| Market Cap | $449.47M |
|---|---|
| Enterprise Value | $442.67M |
| Latest price (Nov 17, 2026) | $8.38 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 41.32% over 52 weeks and trades 1.33% above its 50-day average.
| Beta (1Y) | 1.83 |
|---|---|
| 52-Week Change | +41.32% |
| 1-Month Change | +6.48% |
| 3-Month Change | +23.05% |
| 6-Month Change | +50.45% |
| 5-Year Change | +134.18% |
| 10-Year Change | +134.53% |
| Total Return (1Y) | +41.32% |
| Total Return (3Y CAGR) | +49.84% |
| Total Return (5Y CAGR) | +17.97% |
| Return vs SPY (1Y) | +9.89% |
| Max Drawdown (1Y) | -43.24% |
| Max Drawdown (3Y) | -49.17% |
| Sharpe Ratio (1Y) | 0.34 |
| Correlation with SPY (1Y) | 0.44 |
| 50-Day Average | $8.27 |
| 200-Day Average | $7.18 |
| 52-Week Range | $5.25 to $11.00 |
| RSI (14 Days) | 44.5 |
| Average Volume (20 Days) | 217.94K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.76x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 4.76x |
|---|---|
| Quick Ratio | 4.76x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -140.38% over the last 12 months, against a 5-year average of -46.05%.
| Return on Equity (ROE) | -140.38% |
|---|---|
| Return on Assets (ROA) | -111.28% |
| Return on Capital Employed (ROCE) | -140.07% |
| ROE (5Y Average) | -46.05% |
| ROA (5Y Average) | -42.30% |
| ROIC (5Y Average) | -58.35% |
Scores
DMAC has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was -$28.00K over the last 12 months.
| Revenue | -$28.00K |
|---|---|
| Revenue Growth (YoY) | -100.20% |
| Gross Profit | -$14.00K |
| Operating Income | -$41.81M |
| Pretax Income | -$40.20M |
| Net Income | -$40.23M |
| EBIT | -$40.20M |
| Reported EPS (TTM) | -$0.76 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 79.28% of the $36.15M in total assets.
| Cash and Equivalents | $6.80M |
|---|---|
| Total Debt | $0 |
| Net Cash | $6.80M |
| Net Cash Per Share | $0.13 |
| Working Capital | $28.04M |
| Shareholder Equity | $28.66M |
| Book Value Per Share | $0.53 |
| Total Assets | $36.15M |
| Total Liabilities | $7.49M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $27.00K of capital spending, operating cash flow left -$33.82M of free cash flow.
| Operating Cash Flow | -$33.79M |
|---|---|
| Capital Expenditures | $27.00K |
| Free Cash Flow | -$33.82M |
| FCF Per Share | -$0.63 |
| Depreciation and Amortization | $804.00K |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -5.77% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -5.77% |
Dividends and Yields
DMAC does not pay a dividend. Its free cash flow yield is -7.48%.
| FCF Yield | -7.48% |
|---|---|
| Buyback Yield | -2.59% |
| Shareholder Yield | -2.59% |
Stock Splits
The last split was a 1-for-20 reverse split on Nov 15, 2018.
| Last Split Date | Nov 15, 2018 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:20 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About DMAC
What is DMAC's market cap?
DiaMedica Therapeutics has a market cap of $449.47M. Its enterprise value, which adds debt and subtracts cash, is $442.67M.
How many shares of DMAC are outstanding?
DiaMedica Therapeutics has 53.94M shares outstanding. The count is up 8.69% from a year earlier.
Does DMAC pay a dividend?
No. DiaMedica Therapeutics does not pay a dividend.
How much debt does DMAC have?
DiaMedica Therapeutics has $0 of total debt and $6.80M of cash and equivalents, a net cash position of $6.80M.
DMAC pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors